Revenue

The Company’s revenue from the operations (on consolidate basis) stood at INR 3736.5 Cr for April to June 2018 quarter which was INR 3333.2 Cr a year ago, showing a growth of 12.09% YoY basis. Revenues for the last quarter (Jan to Mar 2018) were INR 3553.9 Cr, shows a growth of 5.14% QoQ basis.

Profit

The Company’s Profit After Tax (PAT) for the quarter ended 30 June 2018 stood at INR 4761 Cr, which was INR 2721 Cr for the period ended 31 March 2018, showing a growth of 75 percent QoQ basis.

Dr. Reddy’s Q1 FY19 Financial Results

• Revenues INR 3,721 Cr [YoY: 12% Up, QoQ: 5% Up]
• Gross Margin 55.7% [01 FY18: 51.6%; 04 FY18: 53.5%]
• SG&A Expenses INR 1,211 Cr [YoY: 3% Up, QoQ: Flat]
• R&D Expenses INR 416 Cr [11.2% of Revenues]
• Profit Before Tax (PBT) INR 501 Cr [13.5% of Revenues]
• Profit After Tax (PAT) INR 456 Cr [12.3% of Revenues]

Words from Co-Chairman and CEO

I am pleased with our Company’s first quarter results, aided by the launch of gSuboxone. Our focus on operational efficiencies has helped in significantly improving our margin profile. Looking ahead, while we may continue to experience price erosion in the North America Generics market, we will also continue to drive growth and cost efficiencies, at the same time, enhancing our quality management systems and building healthy portfolios across the markets we serve.

About Dr Reddy’s Laboratories Ltd

Dr Reddy’s Laboratories Limited is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives through its three businesses; (1) Pharmaceutical Services & Active Ingredients, (2) Global Generics, and (3) Proprietary Products.

Dr Reddy’s offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.

The Company’s major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr Reddy’s operates in markets across the globe. Company’s major markets include – USA, India, Russia & CIS countries, and Europe.

Stock Price Movement

The stock ended up by 2.13% to INR 2132.75 when the market closed! During the quarter ended June 2018, the share price of ACC Limited plunged by more than 7%

Also Read –

1) Finblab’s Valuepick Stock for the month of July 2018 – CEAT Limited

Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I ( Vishal Dalwadi ) or “Fin Blab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.

The post Dr Reddy’s Laboratories Ltd Q1 Results FY18-19: Key Highlights appeared first on Upcoming ipos: Latest news on stocks, economy & finance.